GIOTRIF® (afatinib) is a highly selective irreversible ErbB family blocker1,2

Understand how GIOTRIF® (afatinib) irreversibly blocks aberrant ErbB signalling.

  • Aberrant ErbB family signaling is a key driver in the growth and spread of EGFR M+ NSCLC3
  • GIOTRIF® (afatinib) demonstrates activity against all four members of the ErbB Family: EGFR, HER2, HER4, and indirectly against HER3 by inhibiting its transphosphorylation by heterodimerisation partners1-3
  • This provides potent signal blockade of mutated EGFR and irreversibly silences aberrant ErbB network activity1,2

Want to learn about the indication of GIOTRIF® (afatinib)? Click here to find out more.


EGFR M+=epidermal growth factor receptor mutation positive,

HER=human EGFR, NSCLC=non-small-cell lung cancer


References

1
Solca F, et al. J Pharmacol Exp Ther 2012;343(2):342–350.
2
Li D, et al. Oncogene 2008;27(34):4702–4711.
3
Engelman JA and Cantley LC. Clin Cancer Res. 2006;14(12):4372–4376.

Back to top

This site uses cookies to improve your browsing experience. By using this site, you agree to their use.

Cookie policy
I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information about afatinib for non-small-cell lung cancer treatment.

Country-specific product information

Country-specific product information

Click here for country-specific product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.